

CLINICAL LABORATORY MEDICINE

Tilton

Balows

Hohnadel

Reiss

CLINICAL LABORATORY MEDICINE

Edited by

Richard C. Tilton, Ph.D.

President and Chief Scientific Officer
North American Laboratory Group
New Britain, Connecticut

Albert Balows, Ph.D.

Department of Clinical Pathology and Laboratory Medicine
Emory University School of Medicine;
Director Emeritus
Center for Infectious Diseases
Centers for Disease Control
Atlanta, Georgia

David C. Hohnadel, Ph.D.

Director
Genesee Hospital
Rochester, New York

Robert F. Reiss, M.D.

Professor of Clinical Pathology and Clinical Medicine
College of Physicians and Surgeons
Columbia University;
Director, Transfusion Service
Columbia-Presbyterian Medical Center
New York, New York

with 587 illustrations and 63 color plates

**Mosby
Year Book**

St. Louis Baltimore Boston Chicago London Philadelphia Sydney Toronto

Editor: Stephanie Manning
Developmental editor: Maureen Slaten
Assistant editor: Anne Gunter
Project supervisor: Barbara Bowes Merritt
Book design: Susan Lane
Editing and production: The Wheelley Company

Copyright © 1992 by Mosby-Year Book, Inc.
A Mosby imprint of Mosby-Year Book, Inc.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without prior written permission from the publisher.

Permission to photocopy or reproduce solely for internal or personal use is permitted for libraries or other users registered with the Copyright Clearance Center, provided that the base fee of \$4.00 per chapter plus \$.10 per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, MA 01970. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collected works, or for resale.

Printed in the United States of America

Mosby-Year Book, Inc.
11830 Westline Industrial Drive
St. Louis, Missouri 63146

Library of Congress Cataloging-in-Publication Data

Clinical laboratory medicine/edited by Richard C. Tilton [et al.]
p. cm.

Includes bibliographical references and index

ISBN 0-8016-5873-X

1. Diagnosis, Laboratory. I Tilton, Richard C

[DNLM: 1. Diagnosis, Laboratory I Tilton, Richard C

RB37.C583 1992

616.07'54—dc20

DNLM/DLC

for Library of Congress

92 8370
CIP

Contributors

Nancy L. Anderson, M.M.Sc., M.T. (ASCP)

Associate
Department of Pathology and Laboratory Medicine
Emory University School of Medicine
Atlanta, Georgia

Albert Balows, Ph.D.

Department of Clinical Pathology and Laboratory Medicine
Emory University School of Medicine;
Director Emeritus
Centers for Disease Control
Atlanta, Georgia

Peter A. Benn, Ph.D.

Associate Professor
Director of Laboratory Services
Division of Human Genetics
Department of Pediatrics
University of Connecticut Health Center
Farmington, Connecticut

Mary Kay Boehmer, M.T. (ASCP)

Assistant Administrative Director, Laboratory
Overlook Hospital
Summit, New Jersey

Lawrence W. Bond, Ph.D.

Clinical Chemist and Toxicologist
Department of Pathology
St. Vincent Medical Center
Toledo, Ohio

Marge Brewster, Ph.D.

Professor
Pathology and Pediatrics
University of Arkansas for Medical Sciences;
Clinical Biochemist
Arkansas Children's Hospital
Little Rock, Arkansas

Malcolm L. Brigden, M.D.

Director of Hematology and Microscopy
Island Medical Laboratories
Victoria, British Columbia

Edward R. Burns, M.D.

Associate Professor
Laboratory Medicine and Medicine
Albert Einstein College of Medicine;
Director, Laboratory Hematology
Weiler Hospital of the Albert Einstein College of Medicine
Bronx, New York

Donald J. Cannon, Ph.D.

Associate Professor
Department of Pathology
University of Cincinnati
College of Medicine;
Director of Toxicology
Department of Pathology
Bethesda Hospitals
Cincinnati, Ohio

I-Wen Chen, Ph.D.

Professor
Department of Pathology and Laboratory Medicine, and Radiology
University of Cincinnati
Cincinnati, Ohio

David Ciavarella, M.D.

Associate Professor
Clinical Pathology
New York Medical College;
Director, Hudson Valley Blood Services
Vice-President, New York Blood Center
Valhalla, New York

Norman B. Coffman, Ph.D.

Clinical Chemist
Department of Pathology
Abington Memorial Hospital
Abington, Pennsylvania

John K. Critser, Ph.D.

Director of Andrology Center for Reproduction and
Transplantation Immunology
Methodist Hospital of Indiana, Inc.;
Assistant Professor
Department of Physiology and Biophysics and
Department of Obstetrics and Gynecology
Indiana University Medical School
Indianapolis, Indiana

Mario R. Escobar, Ph.D.

Professor of Pathology
Medical College of Virginia
Richmond, Virginia

William Daniel Follas, M.S.

President
Follas Laboratories, Inc.
Indianapolis, Indiana

Lynne S. Garcia M.S., C.L.S., M.T.

Manager
Clinical Laboratories/Microbiology
Department of Pathology and Laboratory Medicine
University of California at Los Angeles
Los Angeles, California

Petrina V. Genco, Ph.D.

Department of Laboratory Medicine
Medical University of South Carolina
Charleston, South Carolina

Michael A. Gerber, M.D.

Associate Professor
Department of Pediatrics
University of Connecticut School of Medicine
Farmington, Connecticut

Arlene S. Gingras, M.T. (ASCP), SBB

Transfusion Service
Columbia-Presbyterian Medical Center
New York, New York

Joanne M. Griffith, M.A., M.T. (ASCP)

Laboratory Manager
Department of Laboratory Medicine
The Christ Hospital
Cincinnati, Ohio

R. Ian Hardy, M.D., Ph.D.

Department of Obstetrics, Gynecology, and Reproductive Biology
Brigham and Women's Hospital
Harvard Medical School
Boston, Massachusetts

Michael Hassan

Assistant Director
Department of Pathology and Laboratory Medicine
University of Cincinnati School of Medicine
Cincinnati, Ohio

Janet A. Hindler

Senior Specialist
Clinical Microbiology
Department of Pathology and Laboratory Medicine
Clinical Microbiology Section
University of California at Los Angeles
Los Angeles, California

Gordon N. Hoag, M.D., Ph.D.

Director of Clinical Chemistry
Island Medical Laboratories
Victoria, British Columbia

David C. Hohnadel, Ph.D.

Director
Genesee Hospital
Rochester, New York

Gayle B. Jackson, M.S.

Director
Hematology/Immunology
Department of Laboratory Medicine
The Christ Hospital
Cincinnati, Ohio

Sarah H. Jenkins, Ph.D.

Associate Director
Chemistry
Department of Pathology and Laboratory Medicine
University of Cincinnati
Cincinnati, Ohio

Stephen G. Jenkins, Ph.D.

Clinical Assistant Professor of Medicine
University of Florida Medical School;
Director of Clinical Microbiology
Baptist Medical Center
Jacksonville, Florida

Robert C. Jerris, Ph.D.

Director
Clinical Laboratory Sciences Program
Department of Pathology
Emory University School of Medicine
Atlanta, Georgia;
Director, Clinical Microbiology
DeKalb Medical Center
Decatur, Georgia

Carol L. Johnson, M.T. (ASCP) SBB

Coordinator, Technical Education
The New York Blood Center
New York, New York

Harold S. Kaplan, M.D.

Professor and Director, Transfusion Medicine
Department of Pathology
University of Texas
Southwestern Medical Center
Dallas, Texas

Lawrence A. Kaplan, Ph.D.

Associate Professor
Department of Pathology
New York University Medical Center;
Director, Clinical Chemistry and Toxicology Laboratories
Bellevue Hospital
New York, New York

Michael P. Kiley, Ph.D.

Director of Research and Development
Salk Institute
Swiftwater, Pennsylvania

Richard Kowalczyk, Ph.D.

Director of Manufacturing
Boston Biomedica, Inc.
West Bridgewater, Massachusetts

Sandra Larsen, Ph.D.

Chief, Treponemal Pathogenesis and Immunobiology Branch
Division Sexually Transmitted Diseases Laboratory Research
Centers for Disease Control
Atlanta, Georgia

Bonnie Lupo, M.S. (ASCP) SBB

Clinical Instructor
Department of Medical Technology
State University of New York
Stony Brook, New York

Linda M. Mann, Ph.D.

Postdoctoral Fellow
 Department of Pathology and Laboratory Medicine
 Clinical Microbiology Section
 University of California at Los Angeles
 Los Angeles, California

Stanford Marenberg, Ph.D.

Clinical Chemist/Scientific Director Chemistry
 Department of Pathology and Nuclear Medicine
 Kettering Medical Center
 Kettering, Ohio

Melissa Martincich, B.S., M.B.A.

Chief Executive Officer
 North American Laboratory Group
 New Britain, Connecticut

Charles G. Massion, M.D.

Cincinnati, Ohio

Michael D.D. McNeely, M.D.

President
 Island Medical Laboratories
 Victoria, British Columbia

J. Michael Miller, Ph.D.

Chief, Clinical Bacteriology Laboratories
 Centers for Disease Control
 Atlanta, Georgia

Victor Mondy, M.B.A., M.T. (ASCP)

Assistant Supervisor, Chemistry
 Department of Laboratory Medicine
 The Christ Hospital
 Cincinnati, Ohio

Mark A. Neumann, Ph.D.

Co-Director
 Clinical Microbiology, Immunology, and Virology
 Department of Pathology and Laboratory Medicine
 Diagnostic Services, Inc.
 Naples, Florida

David H. Persing, M.D., Ph.D.

Director
 Bacteriology Referral Laboratory
 Section of Clinical Microbiology
 Department of Laboratory Medicine and Pathology
 Mayo Clinic
 Rochester, Minnesota

Amadeo J. Pesce, Ph.D.

Professor
 Pathology and Laboratory Medicine
 University of Cincinnati Medical Center
 Cincinnati, Ohio

Marie Pezzlo, M.A., F(AAM)

Senior Supervisor
 Medical Microbiology Division
 Department of Pathology
 University of California Irvine Medical Center
 Orange, California

Robert F. Reiss, M.D.

Professor of Clinical Pathology and Clinical Medicine
 College of Physicians and Surgeons
 Columbia University;
 Director, Transfusion Service
 Columbia-Presbyterian Medical Center
 New York, New York

Willie Ruff, Ph.D.

Associate Director
 Clinical Laboratories
 Howard University Hospital
 Washington, DC

Paul T. Russell, Ph.D.

Division of Reproduction and Fertility
 The Christ Hospital
 Cincinnati, Ohio

Michael A. Saubolle, Ph.D.

Director, Microbiology/Serology Sections
 Department of Clinical Pathology
 Good Samaritan Regional Medical Center
 Phoenix, Arizona

Ron B. Schiffman, M.D.

Director, Clinical Pathology
 Tucson Veterans Affairs Medical Center;
 Associate Professor of Pathology
 University of Arizona
 Tucson, Arizona

David L. Sewell, Ph.D.

Associate Professor of Pathology
 Oregon Health Sciences University;
 Chief, Microbiology Division
 Laboratory Service
 Veterans Administration Medical Center
 Portland, Oregon

John E. Sherwin, Ph.D.

Director of Chemistry
 Valley Children's Hospital
 Fresno, California;
 Clinical Assistant Professor of Laboratory Medicine
 University of California, San Francisco Medical School
 San Francisco, California

Howard Smith, M.D.

Albany Medical Center Hospital
 Albany, New York

Juan R. Sobenes, M.D.

Director of Clinical Pathology
 Valley Medical Center
 Fresno, California;
 Clinical Assistant Professor of Laboratory Medicine
 University of California, San Francisco
 Medical School
 San Francisco, California

Louis H. Steinert, Ph.D.

Technical Director
 Doctors Clinical Laboratory
 Cincinnati, Ohio

Richard C. Tilton, Ph.D.

President and Chief Scientific Officer
North American Laboratory Group
New Britain, Connecticut

Thomas J. Tinghitella, Ph.D.

Assistant Clinical Professor
Department of Laboratory Medicine
Yale School of Medicine
New Haven, Connecticut;
Department of Pathology
Bridgeport Hospital
Bridgeport, Connecticut

Joan Uehlinger, M.D.

Assistant Professor
Department of Medicine
Albert Einstein College of Medicine
Bronx, New York;
Director, Blood Bank and Transfusion Service
Assistant Attending in Medicine
Montefiore Medical Center
Bronx, New York

Jay E. Valinsky, Ph.D.

Associate Director
Special Diagnostics
The New York Blood Center
New York, New York

Kathy V. Waller, Ph.D.

Assistant Professor
School of Allied Medical Professions
The Ohio State University
Columbus, Ohio

Kory M. Ward, Ph.D.

Assistant Professor
School of Allied Medical Professions
The Ohio State University
Columbus, Ohio

Ann Warner, Ph.D.

Associate Professor
Department of Pathology and Laboratory Medicine;
Associate Director
Division of Toxicology
University of Cincinnati
Cincinnati, Ohio

Melvin P. Weinstein, M.D.

Professor of Medicine and Pathology
University of Medicine and Dentistry of New Jersey
Robert Wood Johnson Medical School;
Director, Microbiology Laboratory
Robert Wood Johnson University Hospital
New Brunswick, New Jersey

Barry Wenz, M.D.

Professor of Laboratory Medicine
Albert Einstein College of Medicine
Bronx, New York;
Director of Clinical Pathology and Immunohematology
Albert Einstein College of Medicine
Bronx, New York

Donald A. Wiebe, Ph.D.

Associate Professor
Department of Pathology and Laboratory Medicine
University of Wisconsin
Madison, Wisconsin

Marie Zureick, M.T. (ASCP)

The Christ Hospital
Cincinnati, Ohio

Preface

Continued growth and increasing complexity are words frequently used to describe many scientific disciplines. Laboratory medicine, a multifaceted discipline with seemingly unabated growth and complexity, definitely falls under this rubric.

Technological advances, coupled with a growing battery of diagnostic skills, have led to the development of many innovative and far-reaching approaches to the laboratory diagnosis of disease. Some of these new approaches include rapid screening tests that provide prompt and useful general information, whereas other analyses are highly automated, sensitive, and specific, which not only yield results in support of a diagnosis, but other levels of information as well. Laboratory medicine provides data that help formulate therapy, promote the patient's recovery, and help establish the need for dietary, environmental, and physiological changes that contribute to the maintenance of good health.

Laboratory medicine specialists not only determine the methodology of the tests offered and control technical quality, but also consult with the medical staff to interpret test results and give advice on the role of the laboratory to resolve diagnostic dilemmas.

Other facets of laboratory medicine include the provision of laboratory support for public health activities and epidemiological investigations, evaluation of persons for drug abuse, and medicolegal investigations. The staff of the clinical laboratory also frames and implements institutional guidelines and procedures to control nosocomial infections, monitors sterilization and disinfection procedures, and con-

sults for the proper disposal of medical waste. The laboratory staff must also be familiar with the growing number and variety of rules, regulations, and recommendations that come from local, state, and federal government and professional organizations.

At times it may appear that these constraints place added emphasis on the test results and diminished emphasis on the knowledge and skill of laboratory personnel. Regardless of such appearances, and regardless of the size, location, or scope of services offered by a clinical laboratory, the one requirement that transcends all others is the need for a staff of individuals who are knowledgeable and technically proficient.

This textbook attempts to bring together the method selection and decision-making processes that ensure quality laboratory testing and to correlate the laboratory data obtained with current understanding of disease pathophysiology and clinical management of patients. The editors and authors have labored diligently to produce a book that will be a companion to students, a resource to the laboratory medicine specialist, and a reference to the clinician who wishes to optimally utilize the clinical laboratory.

**Richard C. Tilton
Albert Balows
David C. Hohnadel
Robert F. Reiss**

Contents

PART ONE

INTRODUCTION TO LABORATORY MEDICINE

- 1** Laboratory organization and management, 2
Richard C. Tilton
Melissa Martincich
- 2** Clinical laboratory safety, biohazard surveillance, and infection control, 13
Michael P. Kiley
- 3** Sample collection and processing, 25
Joanne M. Griffith
- 4** Weights, measures, and principles of instrumentation, 40
Marie Zureick
- 5** Laboratory statistics, reference ranges, and quality control, 66
Mary Kay Boehmer

PART TWO

MEDICAL CHEMISTRY AND CHEMICAL ANALYSIS

David C. Hohnadel

- 6** Renal physiology and water and electrolyte balance, 84
Lawrence A. Kaplan
- 7** pH and blood gases, 98
Sarah H. Jenkins
- 8** Carbohydrates, 109
Juan R. Sobenes
John E. Sherwin
- 9** Lipids, 125
Donald A. Wiebe
- 10** Bone and mineral metabolism and parathyroid hormones, 135
Willie Ruff
- 11** Hemoglobin and iron, 145
Gayle B. Jackson

- 12** Proteins, 157
Kory M. Ward
Kathy V. Waller
- 13** Liver function and nitrogen metabolism, 179
John E. Sherwin
Juan R. Sobenes
- 14** Clinical enzymology, 190
David C. Hohnadel
- 15** Pancreatic and intestinal function, 208
Michael D.D. McNeely
- 16** Pituitary, hypothalamic, and adrenal hormones, 222
Richard Kowalczyk
- 17** Thyroid function, 253
I-Wen Chen
Howard Smith
- 18** Gonadal hormones, 289
Paul T. Russell
R. Ian Hardy
- 19** Fertility, pregnancy, and fetal maturity, 290
Paul T. Russell
R. Ian Hardy
- 20** Vitamins, 307
Marge Brewster
- 21** Tumor markers, 322
Lawrence W. Bond
- 22** Laboratory investigation of sexual assault, 330
Charles G. Massion

PART THREE

TOXICOLOGY, HEAVY METALS, AND THERAPEUTIC DRUG MONITORING

David C. Hohnadel

- 23** Basic pharmacokinetics, 334
Ann Warner
- 24** Techniques of drug analysis, 346
Louis H. Steinert
Norman B. Coffman

- 25** Heavy metal analysis, 363
Donald J. Cannon
- 26** Therapeutic drug monitoring and antibiotics, 375
Victor Mondy
- 27** Emergency overdose toxicology, 384
Michael Hassan
- 28** Legal aspects of drug screening, 393
Amadeo J. Pesce

PART FOUR

URINALYSIS, CLINICAL MICROSCOPY, AND FLUIDS

David C. Hohnadel

- 29** Urinalysis, 402
Michael D.D. McNeely
Malcolm L. Brigden
- 30** Serous, cystic, and synovial fluid analysis, 422
Gordon N. Hoag
Michael D.D. McNeely
Malcolm L. Brigden
- 31** Seminal fluid analysis, 425
William Daniel Follas
John K. Critser
- 32** Gastrin and gastric fluid analysis, 446
Stanford Marenberg

PART FIVE

IMMUNOLOGY

Richard C. Tilton

- 33** Immunobiology, immunochemistry, and immunopathology, 448
Mario R. Escobar
- 34** Antibody detection for the diagnosis of infectious disease, 467
Thomas J. Tinghitella
- 35** The human leukocyte antigen system, 476
Petrina V. Genco
- 36** Immunodeficiencies and autoimmune disorders, 485
Gayle B. Jackson

PART SIX

CLINICAL MICROBIOLOGY

Albert Balows

- 37** Contemporary approaches to clinical microbiology, 506
Albert Balows

- 38** Quality assurance in clinical microbiology, 511
Ron B. Schiffman
- 39** Specimen collection, transport, and initial processing, 523
Richard C. Tilton
- 40** Principles and practices for the laboratory guidance of antimicrobial therapy, 532
Janet A. Hindler
Linda M. Mann
- 41** Microbial antigen detection, 565
Richard C. Tilton
- 42** Nucleic acid amplification techniques for the diagnosis of infectious diseases, 572
David H. Persing

PART SEVEN

MICROBIOLOGICAL ANALYSIS OF CLINICAL SPECIMENS

Albert Balows

- 43** Upper respiratory tract specimens, 584
Michael A. Gerber
- 44** Lower respiratory tract specimens, 591
Michael A. Saubolle
- 45** Central nervous system specimens, 604
Stephen G. Jenkins
- 46** Eye and ear specimens, 614
Stephen G. Jenkins
- 47** Gastrointestinal tract specimens, 627
J. Michael Miller
- 48** Urinary tract specimens, 633
Marie Pezzlo
- 49** Blood specimens, 641
Melvin P. Weinstein
- 50** Genital specimens, 649
Sandra Larsen
- 51** Wound, body fluid, and surgical specimens, 662
Robert C. Jerris
- 52** Hair, skin, and nail specimens, 673
Nancy L. Anderson

PART EIGHT

THE SYSTEMATIC IDENTIFICATION OF CLINICALLY SIGNIFICANT MICROORGANISMS

Albert Balows

- 53** Bacteriology, 686
David L. Sewell

- 54** Fungi, 727
Richard C. Tilton
- 55** Viruses, 765
Mark A. Neumann
- 56** Parasites, 792
Lynne S. Garcia

PART NINE**HEMATOLOGY**

Robert F. Reiss

- 57** Hemopoiesis and cell kinetics, 812
Jay E. Valinsky
- 58** Morphology of the hematopoietic system, 830
Robert F. Reiss
- 59** Quantitative evaluation of the hematopoietic system, 859
Edward R. Burns
Barry Wenz
- 60** Flow cytometry and phenotyping of hemopoietic cells, 879
Jay E. Valinsky
- 61** Laboratory diagnosis of erythroid disorders, 898
Robert F. Reiss
- 62** Laboratory diagnosis of granulocyte disorders, 938
Robert F. Reiss
- 63** Laboratory diagnosis of lymphoid disorders, 961
Robert F. Reiss

PART TEN**HEMOSTASIS**

Robert F. Reiss

- 64** Normal hemostasis, 996
Robert F. Reiss
- 65** Laboratory evaluation of hemostasis, 1007
Robert F. Reiss
- 66** Laboratory diagnosis of hemorrhagic disorders, 1025
Robert F. Reiss

- 67** Laboratory diagnosis and management of thrombotic disorders, 1045
David Ciavarella

PART ELEVEN**IMMUNOHEMATOLOGY AND TRANSFUSION PRACTICE**

Robert F. Reiss

- 68** Blood group antigens and antibodies, 1064
Carol L. Johnson
- 69** Laboratory techniques in immunohematology, 1084
Arlene S. Gingras
- 70** Immune hemolysis, 1101
Robert F. Reiss
- 71** Blood collection, processing, and storage, 1109
Joan Uehlinger
- 72** Transfusion of blood components and fractions, 1121
Robert F. Reiss
- 73** Complications of blood transfusion, 1132
Harold S. Kaplan

PART TWELVE**CYTOGENETICS**

- 74** Cytogenetics, 1144
Peter A. Benn

APPENDICES

Chemistry Reference Intervals, 1168
Periodic Table of the Elements, 1178

COLOR PLATES

1 to 65 following page 562

INTRODUCTION TO LABORATORY MEDICINE

1

Laboratory organization and management

Richard C. Tilton
Melissa Martincich

This chapter briefly presents some guidelines for the organization and management of a clinical laboratory. The presentation is neither exhaustive nor comprehensive. Rather, it is designed to stimulate questions regarding laboratory management, to provide an outline of necessary administrative functions, and to introduce fundamental information to laboratorians whose primary tasks may be analytical rather than administrative.

LABORATORY STRUCTURE

Traditional laboratory administrative structure has developed from an organization plan that was originally designed to implement laboratory testing in the most efficient manner. Figure 1-1 depicts this simple structure.

The laboratory was usually administered by a pathologist whose chief role in the hospital was in anatomic pathology. Supervisors in each of the laboratory sections reported to the chief technologist. There was little administrative distinction between the clinical laboratory and pathology department. The laboratory, being a high profit center, underwrote losses incurred by other non-revenue generating hospital functions. The last decade, however, has seen significant change, not only in how the laboratory relates to the hospital in a fiscal sense, but how the laboratory interacts in an increasingly complex and highly regulated health care environment. Figure 1-2 more typically portrays the laboratory of the 1990s. This table of organization is more characteristic of a commercial laboratory, but as hospital clinical laboratories develop outreach programs or spin-off for profit facilities, the distinctions become less apparent.

Whereas tables of organization may differ markedly from institution to institution, the point to be made is the growing complexity of laboratory medicine as a discipline, now separate and distinct from pathology services. Doctoral scientists and pathologists may not be hospital employees, but may be partners in a group practice that lease laboratory space from the hospital.

New health care financing plans (DRGs, Medicare, HMO's) have seriously limited profitability of the laboratory. Consequently, as a result of regulatory constraint, a new focus on laboratory management has emerged. Lines of authority once traditionally controlled by the laboratory

are now managed by hospital administration. No value judgment should be placed on these changes, only the recognition that hospital ancillary services management has become an enigma; that is, how to administer a technologically burgeoning organization in an environment of severe fiscal constraint, regulation, and oversight.

THE INTERFACE OF LABORATORY SCIENCE AND BUSINESS

Laboratory services annually constitute a multibillion dollar health care expenditure. Yet, in many respects, the laboratory has not caught up with the changing face of medical practice. The clinical laboratory must provide service in a complex environment of:

- Decreased hospital inpatient census
- Expanded outpatient medicine, i.e., surgery centers, and so on
- Shortened inpatient stays
- Inpatients requiring major therapeutic intervention and intensive support systems, i.e., critically ill inpatients
- Demand for rapid turnaround time for laboratory tests
- Point-of-use testing
- Long-term (non-hospital) care facilities with an increasing role in acute care
- Large group practices with increased need for a wide variety of tests
- Increased patient expectations of quality and cost containment

Laboratories have struggled to meet these needs and changes in a variety of ways, including the following:

- Active marketing of laboratory services within the community to maximize profit.
- Satellite laboratories specializing in point-of-use testing, particularly to support single day medical intervention clinics, operating rooms, intensive care units.
- Electronic communication and information transfer to reduce turnaround time.
- Mechanization and automation of laboratory procedures to minimize use of a shrinking work force.
- Increased use of private reference laboratories for non-profitable testing.




Fig. 1-1 A traditional table of organization for a small clinical laboratory.

Laboratory Organizational Chart




Fig. 1-2 A typical laboratory table of organization. (Modified from Mattice and Associates, Vancouver: 1991.)

- Trends toward centralization of laboratories within communities or specialty allocation (hospital A does endocrinology, hospital B does immunology).

There has also been a blurring of intralaboratory turf because of changing technology and manpower utilization. For example, hepatitis and human immunodeficiency virus (HIV) serology may be done through the blood bank, automated testing for infectious disease through the chemistry laboratory, and urinalysis through the microbiology laboratory. Almost all primary care physicians in the United States have access to an office laboratory. There is active marketing and sales of small, cost-effective analyzers that can perform chemistry profiles and enzyme-linked immunosorbent assays (ELISAs), as well as single use rapid tests for group A streptococcus, *Chlamydia*, and several other infectious disease agents. Such changes may radically alter the balance of testing between the hospital laboratory and

the physician office laboratory (POL). Existing and emerging restrictions on POLs regarding personnel qualifications and quality control, promulgated in 1992 as a result of the Clinical Laboratory Improvement Act of 1988 (CLIA 1988), may again affect this delicate balance.

The increase in self-testing cannot be ignored and is best illustrated by home pregnancy and ovulation kits, as well as home monitoring of blood glucose by diabetics.

LABORATORY FINANCIAL PLANNING

The contemporary laboratory is financially complex as well as technically sophisticated. Annual budget development time is not the favorite time of year for most laboratories. However, because of the changing nature of laboratory services, all must recognize that the operating budget and the financial plan are the critical interfaces between medicine and business. In fact, most organizations now rely on ac-

counting professionals to organize and prepare their periodic financial status reports. However, it is critical for laboratory staff to appreciate the variety of management tasks and reports required to ensure the success of what is often a multimillion dollar business. For even a small laboratory, some elements of financial planning include:

- Income from laboratory tests (prediction of increases or decreases in test volume by laboratory section)
- Numbers of personnel required to satisfy sales forecasts
- Assessment of personnel productivity (e.g., College of American Pathologists [CAP] Workload Recording Plan)
- Anticipated needs in reagents, supplies, disposables
- Anticipated union contracts or budgeted pay increases
- Cost of continuing education
- Debt service (if any)
- Capital equipment (new and replacement)
- Quality assurance costs (external proficiency testing, etc.)
- Plan for monitoring variable costs
- Plan to control costs once budget is accepted
- Analysis of individual test fees; determination of margin for each test performed in laboratory
- Estimate of laboratory overhead (utilities, etc.)

PERSONNEL

Regardless of the layers of federal, state, and private regulations of the clinical laboratory, innumerable quality assurance (QA) probes, and internal and external test quality control, the best assurance that a laboratory reports accurate, reproducible results is the quality of personnel who perform the tests. Several personnel issues are critically important and are outlined here.

Educational background

There has been a tendency for federal agencies to attempt to lower personnel standards by minimizing the need for formal education in the clinical laboratory sciences. Increasingly complex instruments, molecular diagnosis, and demands for increased quality and rapid turnaround time clearly indicate that all laboratory personnel must be better educated and trained. For example, that a baccalaureate degree should be the minimum requirement for a technologist, and an associate degree the minimum requirement for a technician.

Certification

Certification of scientific and clinical competency by examination is a necessary prerequisite for a quality work force. There are a number of certifying agencies, such as the American Society for Clinical Pathology (ASCP), the American Academy of Microbiology, and the American Association of Clinical Chemistry. Personnel must be encouraged to become certified and their successful efforts rewarded with salary increases.

Continuing education

Continuing education is becoming increasingly expensive. However, continuing education is essential (mandatory if the laboratory is CAP accredited) to guarantee that workers who are judged competent by possession of a degree and

certification continue to remain knowledgeable of the many changes in laboratory medicine. Some of the best continuing education classes are sponsored by local and regional groups such as the American Society for Medical Technologists (ASMT) and the laboratory specialty associations. Similarly, local programs exist for all specialty areas of the laboratory.

Once the laboratory has set in place a system for judging initial quality of applicants and increasing their competency through education, then other personnel issues become critically important to both the professional and the technical staff.

These issues include:

- Laboratory safety and health
- Career development and advancement (career ladders)
- Pleasant working environment
- Schedules of time off, vacations, etc., that are fair and consistent with the need to provide adequate clinical laboratory support

MANAGEMENT PHILOSOPHY AND STYLE

Volumes have been written about, degrees have been given for, and courses have been designed around the philosophy of management and how best to select a style that maximizes the talent of the employees and the strength of the management team. Some caveats that may prove useful include:

- **Manage By Objectives (MBO):** Set reasonable, attainable goals and provide tools for the work force to achieve those goals. An example of a goal might be to achieve 100% success in the parasitology proficiency testing program or in an area in which the laboratory has been weak.
- **Manage By Example (MBE):** Don't expect high performance of others if you cannot or are unwilling to measure up to the same standards of performance.
- **Manage By Consensus (MBC):** Seek advice of staff before making a management decision, recognizing that some decisions cannot be made by consensus and may not be popular.
- **Avoid or discourage destructive conflict:** In any group of interacting individuals, conflict management may be the skill that is most difficult to learn and the hardest to practice.
- **Praise in public, admonish in private:** Publicize the efforts of exemplary employees, but do not publicly chastise an employee or hold him or her up to criticism in the presence of fellow workers.

Whereas MBO is still the favorite management style in most laboratories, a combination of MBO, MBE, and MBC may be preferable in certain instances.

QUALITY CONTROL/QUALITY ASSURANCE

The scope of most clinical laboratories is now so broad and the interactions between laboratory technical operations, professional consultation, marketing, and finance so complex that the laboratory management is better served by the professional manager. Thus, the medical or scientific director of the laboratory should be relieved of much of the responsibility of the day-to-day management functions. However, the advent of professional laboratory managers has not diminished the role of the pathologist or clinical

laboratory scientist; it has allowed them to play a much more proactive role in what is clearly the most important and also the most difficult part of the laboratory operation—quality assurance. The dilemma faced by all laboratorians is how to maintain the balance between financial constraints and high quality output. The clinical laboratory exists to provide data that assist clinicians in making medical decisions. Laboratory medicine uses successful outcome to measure quality. That is, quality is result-oriented. One has only to look at new stringent proficiency testing requirements in CLIA 1988 in contrast to a growing egalitarianism in personnel standards to understand the trend. Throughout this book, the chapters that follow discuss and review quality control guidelines. The laboratorian is advised to pay close attention to avoid some very unpleasant sanctions by one or more regulatory agencies.

REGULATION

Laboratories are regulated by local, state, private, and federal agencies. A single laboratory may be inspected and/or proficiency tested by the state in which it resides, the city in which it intends to do business, the College of American Pathology (CAP), the American Association of Blood Banks, the American Board of Bioanalysts, the Joint Commission on the Accreditation of Hospitals (JCAOH), HCFA, and other agencies of the Department of Health and Human Services. Regulations are in dynamic flux to the extent that guidelines presented today may be changed tomorrow. It is impossible to even summarize all of the regulations pertaining to the operation of a clinical laboratory. However, some of the more pertinent ones are presented with the understanding that they are subject to change and may vary as some state regulations take precedence.

The basis for federal regulation of laboratories, in particular those involved in interstate testing, has been the Clinical Laboratory Improvement Act (CLIA) of 1967. An outline of the evolution of CLIA from 1967 to 1991 follows.

Clinical laboratory improvement act of 1967

- Regulates interstate testing for independent laboratories
- Adopts Medicare standards for technical personnel
- Exempts hospital laboratories
- Requires proficiency testing
- Is administered by the Centers for Disease Control (CDC) in Atlanta

Initially, a laboratory designated as being able to receive fees for service for tests performed on Medicare and Medicaid patients had to operate under somewhat different regulations than a laboratory (even the same laboratory) operating under CLIA-67. In 1988, new legislation under CLIA-88 brought all laboratories under a single set of rules for payments and regulations for patients, personnel qualifications and provision of certain laboratory tests. Final rules were published in 1990 and were effective September 10, 1990. Proficiency testing under these new rules was effective January 1, 1991. It should be noted that many of these revisions were incorporated into CLIA 1988.

There are some exceptions to CLIA 1967 (revised). Rules *do not apply* to physician office laboratories who only test their own patients, health maintenance organizations (HMOs) and rural health clinic laboratories, insurance test-

ing laboratories, and specimen collection and mailing facilities who do not perform tests.

Under the CLIA 1967 (revised) and CLIA 1988, laboratories must comply with all federal, state, and local laws regarding health and safety of patients, laboratory licensure, staff licensure, fire safety, and handling, storage, and disposal of hazardous materials.

One of the most important aspects of the CLIA is proficiency testing. Proficiency testing specimens must be tested using the laboratory's routine procedures. There may be no discussion of proficiency testing results among laboratories. Unsuccessful participation is defined as two consecutive or two out of three unsatisfactory testing events, or two out of three failing scores for the same analyte. The number of samples has been increased to five per event. A satisfactory score is at least 80% (100% for immunohematology). Before Medicare or CLIA certification can be issued, a laboratory must receive a satisfactory score in one proficiency testing event.

The most radical changes brought about by CLIA 1967 (revised) and CLIA 1988 are evident in cytology. Changes include the following:

- Workload limit of 120 slides in 24-hour period
- Maximum number of 120 slides must be examined in no less than 6 hours
- Limit of 80 unevaluated slides per day, the remaining 40 slides can be examined for quality control purposes only
- More stringent requirements for record keeping, quality control, and quality assurance

Cytology proficiency testing is summarized as follows:

- One proficiency test performed annually at designated testing site
- One proficiency test performed annually that was unannounced on-site
- Each cytotechnologist must take part in two proficiency test events per year
- A score of at least 80% must be attained
- If a score of less than 80% is achieved, the last 500 slides examined by that individual must be reexamined by a cytotechnologist who passed

For all sections of the laboratory, there are new requirements for patient test management:

- Written specimen labeling instructions for clients
- Test requisition to include age, sex, date of birth, and clinical information
- Preliminary laboratory results must be kept for 2 years
- Pathology reports must be kept for 10 years
- "Panic" (results that require immediate attention) value reporting procedure must be in place

Quality assurance/quality control measures for all laboratory sections include the establishment of policies and procedures to: (1) monitor and evaluate quality; (2) identify and correct problems; (3) assure prompt, accurate, and reliable result reporting; and (4) assure that the laboratory is adequately and competently staffed.

More specifically, the following measures should be taken:

- Facility ventilation must be adequate for testing and reporting.
- Temperature and humidity must be monitored.

- There can be no mixing of kit components of different lots.
- A procedure manual including instructions for slide preparations and calculations must be maintained.
- Daily equipment function checks must be performed before patient testing.
- Adherence to equipment manufacturers' quality control recommendations.
- Quality control procedures for equipment are to be performed at least each day of use.
- More stringent calibration and verification requirements are necessary.
- Control samples should be tested in the same manner as patient's samples.
- Immunohematology records should be kept for 5 years.

For hospital-based laboratories, the laboratory director must be either a pathologist (MD/DO) with laboratory training and experience, or have a PhD in the life sciences with laboratory training and experience, or be a director qualified under state law.

Technical supervisors are required if the laboratory performs testing in the following areas:

- Histocompatibility
- Histopathology
- Blood banking
- Cytology
- Clinical cytogenetics
- Dermatopathology
- Transfusion services
- Oral pathology

Other personnel standards have been proposed under CLIA 1988 based on the complexity of laboratory testing. However, it is not anticipated that personnel requirements for hospital laboratories will change. The Clinical Laboratory Improvement Act of 1988, to be administered by the Health Care Financing Administration (HCFA), was prompted by the "Pap Smear Scandal" and the fact that relatively few states (14) have laboratory licensure laws. The process of rule making has been tortuous and final rules, after much debate, are to be published by January of 1992. Some additional features of CLIA 1988 include:

- Varying standards based on test complexity: "simple testing, moderately complex, highly complex" testing
- The requirement that all laboratories, except Department of Veteran Affairs (VA) laboratories, research laboratories, and insurance testing laboratories must have either a waiver or a certificate
- User fees to finance the program
- Proficiency test standards, further tightened over CLIA 1967 (revised), to come into effect in January of 1994
- Provision for publishing a list of problem laboratories

Under the present proposed rules, a waiver will be granted to laboratories performing only the following tests (these laboratories will, in most instances, be physician office-based):

- Urine dipstick or tablet urinalysis
- Ovulation tests
- Urine pregnancy tests
- Fecal occult blood
- Hemoglobin (copper sulfate)
- Erythrocyte sedimentation rate

The majority of these tests are available to patients in

over-the-counter test kits. There are no personnel requirements for a laboratory performing only waived tests. Personnel requirements have been published, however, for a moderately complex laboratory. They include requirements for laboratory director, technical consultant, clinical consultant, and testing personnel. For a highly complex laboratory, all of the above are included along with technical supervisor, general supervisor, and testing personnel assistant.

There are enforcement procedures that will interconnect state, federal, and private accrediting agencies. It will be impossible to be sanctioned by one agency and continue to operate under another agency. Sanctions include suspension, revocation, or limitation of license, denial of Medicare payment, and civil penalties including fines and jail terms.

Not all sanctions can be appealed. For example, if it is determined not to reinstate a CLIA certificate, this action cannot be appealed. In addition to CLIA 1967 (revised) and CLIA 1988, there are a number of other laws that have been introduced or passed. They include:

- The Stark Amendment: This deals with physician test referral to laboratories in which physicians have an interest
- Safe Harbors: delineates fraud and abuse practices relevant to clinical laboratories
- Medicare/Medicaid Anti-Kickback Act of 1977
- Rural Laboratory Personnel Shortage Act
- A variety of health care reform bills

INTERACTION WITH REFERENCE LABORATORIES

Very few, if any, clinical laboratories performs all of their requested testing in-house. Therefore, the use and selection of a reference laboratory is virtually universal. Choosing a reference laboratory should be based on quality, service, turnaround time, and accessibility of experts for consultation. Fiscal restraint often dictates that the decision may be made based on the lowest bid for laboratory services. Such low bid situations are not always satisfactory. The laboratory is usually left to make a most important decision, whether or not to send out the test or perform it in-house. Certain elements outlined in Box 1-1 should be considered when making such a decision.

It is recommended that laboratories designate one person to coordinate reference laboratory testing and develop a workflow for the referral process. Box 1-2 outlines some typical tasks of a "send out" section.

There are many problems that can arise when using reference laboratories. Most can be avoided by developing a working relationship with a responsible and knowledgeable person at the reference laboratory. This is most often the client services coordinator. Problems such as STAT pickups, unreliable courier service, inaccessibility of technical people, lost specimens, or misunderstood or missing interpretation of data must be reconciled before a professional partnership between the client and the reference laboratory is a reality. The most common problem encountered is too long a turnaround time, which results in physicians calling to find out test results. Many reference laboratories provide a list of expected turnaround times, but they produce a test schedule less often. With both lists, the referring laboratory